L-glutamine positive for Emmaus, commercial prospects unclear
This article was originally published in Scrip
Executive Summary
A pharmaceutical-grade L-glutamine developed by Emmaus Life Sciences reduced the frequency of sickle cell crises and hospitalizations in a Phase III clinical trial, but questions remain about the commercial market for a product that's available as an over-the-counter supplement.